FORM PTO-1449

/ 00 - -

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

> (Use several sheets if necessary) MAY 0 3 1999

ATTY. DOCKET NO. 238/046

SERIAL NO. 09/186,475

APPLICANT:

FILING DATE:

Annie Fong et al.

GROUP: November 4, 1998 1614

U.S. PATES DOCUMENTS EXAMINER FILING SUB DOCUMENT NUMBER INITIAL DATE NAME CLASS CLASS DATE AA 3/8/83 4,376,110 David et al. 436 548 8/4/80

FOREIGN PATENT DOCUMENTS								
EXAMINER						SUB	TRANSI	ATION
INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
(D)	AB	96/22976	01.08.96	WO/PCT (Buzzetti et al.)				
(D)	AC	96/40116	19.12.96	WO/PCT (Tang et al.)				

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
0	AD	Adamson et al., "Urinary tissue factor levels in prostatic carcinoma: A potential marker of metastatic spread?" The British Journal of Urology 71:587-592 (1993)
6	AE	Adnane et al., "BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers," Oncogene 6:659-663 (1991)
(S)	AF	Akbasak and Sunar-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)
	AG	Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," J. Clin. Invest. 84:1418-1423 (1989)
$\langle \chi \rangle$	AH	Baserga, "Oncogenes and the Strategy of Growth Factors," Cell 79:927-930 (1994)
	AI	Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" Cancer Research 55:249-252 (1995)
(DV)	AJ	Bell, "The fibrinolytic system in neoplasia," Semin. Thromb. Hemost. 22:459-478 (1996)
6	AK	Bellus et al., "A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia," Nature Genetics 10:357-359 (1995)
(A)	AL	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," FASEB J. 6:3403-3409 (1992)
6	AM	Carmeliet et al., "Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system," Ann. N.Y. Acad. Sci. 811:191-206 (1997)
D)	AN	Clauss et al., "Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: Functional analysis of the tumor necrosis factor receptors," FEBS Letters 390:334-338 (1996)
3	АО	Conkling et al., "Clinical trials with human tumor necrosis factor: In vivo and in vitro effects on human mononuclear phagocyte function," Cancer Research 48:5604-5609 (1988)
Ø	AP	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," Molecular and Cellular Biology 14:4588-4595 (1994)
9	AQ	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)

EXAMINER:	<i>i</i> -	DATE CONSIDERED:	_
//		10 -	31-01
		<u> </u>	
and the second and the second			

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Information Disclosure Statement - Section 9 PTO-1449

Page 1 of 4.

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMEN E

(Use several sheets if necessary)
MAY 0 3 1533

ATTY. DOCKET NO. 238/046

SERIAL NO. 09/186,475

APPLICANT: Annie Fong et al.

FILING DATE: November 4, 1998 **GROUP:** 1614

	<u> </u>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	l	Denekamp, "Review article: Angiogenesis, neovascular proliferation and vascular
$ A\rangle$	AR	pathophysiology as targets for cancer therapy," The British Journal of Radiology 66:181-
<u>U</u>	<u> </u>	196 (1993)
200	AS	Deng et al., "Fibroblast growth factor receptor 3 is a negative regulator of bone growth,"
(D8		<u>Cell</u> 84:911-921 (1996)
×	AT	Dickson et al., "Tyrosine kinase receptor – nuclear protooncogene interactions in breast
Ø	'''	cancer," Cancer Treatment Res. 61:249-273 (1992)
8	AU	Doldi et al., "Vascular endothelial growth factor messenger ribonucleic acid expression in
00		human ovarian and endometrial cancer," Gynecol. Endocrinol. 10:375-382 (1996)
an.		Falanga et al., "Loss of blast cell procoagulant activity and improvement of hemostatic
0	AV	variable is patients with acute promyelocytic leukemia administered all-trans-retinoic
	 	acid," <u>Blood</u> 86:1072-1081 (1995)
(D)	414	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth
(U»	AW	Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research</u>
	<u> </u>	Communications 161:851-858 (1989)
M	AX	Ferrer et al., "Vascular endothelial growth factor (VEGF) expression in human prostate
(0)	~~	cancer: In situ and in vitro expression of VEGF by human prostate cancer cells," <u>J. Urol.</u>
		157:2329-2333 (1997) Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and
$ \mathcal{M} $	AY	in vivo," Kidney International 43:S47-S54 (1993)
	AZ	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992)
	BA	Folkman et al., "Angiogenic factors," <u>Science</u> 236:442-447 (1987)
		Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" Journal of
	BB	the National Cancer Institute 82:4-6 (1990)
<u></u>	ВС	Folkman, "Ch. 24. Angiogenesis," Congress of Thrombosis and Haemostasis (Verstraete
COY	ВС	et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
(M)	BD	Fritsche, "Serum tumor markers for patient monitoring: A case-oriented approach
COV		illustrated with carcinoembryonic antigen," Clin. Chem. 39:2431-2434 (1993)
M	BE	Goldring and Goldring, "Cytokines and Cell Growth Control," Critical Reviews in
LQ"		Eukaryotic Gene Expression 1:301-326 (1991)
12	BF	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by
9		Genetic and Proteolytic Mechanisms," J. Biol. Chem. 267:26031-26037 (1992)
180	BG	Hu et al., "Synthesis of tissue factor messenger RNA and procoagulant activity in breast
0.		cancer cells in response to serum stimulation," <u>Thrombosis Research</u> 72:155-168 (1993)
$\langle \mathcal{A} \rangle$	вн	Iwasaka et al., "Ets-1 regulates angiogenesis by inducing the expression of urokinase-
(O)	ВΠ	type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular
<u> </u>		endothelial cells," J. Cell. Physiol. 169:522-531 (1996)
$\langle \gamma \rangle$	ВІ	Jabs et al., "Jackson-Weiss and Crouzon syndromes are allelic with mutations in fiborblast growth factor receptor 2," Nature Genetics 8:275-279 (1994)
$ \langle \alpha \rangle $	BJ	Jaye et al., "Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction," <u>Biochem. Biophys. Acta.</u> 1135:185-199 (1992)
× (Klagsbrun and Soker, "VEGF/VPF: the angiogenesis factor found?" Current Biology
(0)	BK	3:699-702 (1993)f
~		Klagsbrun et al., "Biological and biochemical properties of fibroblast growth factors,"
900	BL	Arteriosclerosis 9:269-278 (1989)
		Kluth et al., "Endothelial expression of CD40 in renal cell carcinoma," Cancer Research
(0)	ВМ	57:891-899 (1997)
(2)	DN	Kohler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined
$ (\sigma) $	BN	specificity," Nature 256:495-497 (1975)

EXAMINER: DATE CONSIDERED: 10-31-07

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449	ATTY. DOCKET NO. 238/046	SERIAL NO. 09/186,475
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Annie Fong et al.	
(Use several sheets if necessary) MAY 0 3 1593	FILING DATE: November 4, 1998	GROUP: 1614

G TRADE WALL					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human					
	l '	Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal			
1 AS 1	ВО	Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360			
(Jh)	f '	(1992)			
		Kumabe et al., "Amplification of α-platelet-derived growth factor receptor gene lacking an			
00	BP	exon coding for a portion of the extracellular region in a primary brain tumor of glial			
<i>(()</i> }/	'	origin," <u>Oncogene</u> 7:627-633 (1992)			
	 	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein			
	BQ	abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992)			
- A		Luther et al., "Tissue factor expression in normal and abnormal mammary gland," Nature			
	BR	Medicine 2:491-492 (1996)			
1		Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung			
	BS	cancer cell lines and fresh tumor cells," Cancer Research 50:2511-2517 (1990)			
80	<u> </u>	Mandriota et al., "Vascular endothelial growth factor increases urokinase receptor			
(0)	ВТ	expression in vascular endothelial cells," <u>J. Biol. Chem.</u> 270:9709-9716 (1995)			
		McLaren et al., "Vascular endothelial growth factor is produced by peritoneal fluid			
\square	BU	macrophages in endometriosis and is regulated by ovarian steroids," J. Clin. Invest.			
6		98:482-489 (1996)			
	<u> </u>	Mohammadi et al., "Identification of six novel autophosphorylation sites on fibroblast			
	BV	growth factor receptor 1 and elucidation of their importance in receptor activation and			
(P)	- '	signal transduction," Mol. Cell Biol. 16:977-989 (1996)			
	73.4	Muenke et al., "A common mutation in the fibroblast growth factor receptor 1 gene in			
1 /2/	BW	Pfeiffer syndrome," Nature Genetics 8:269-274 (1994)			
16		Plate et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in			
0	вх	human gilomas in vivo," Nature 359:845-848 (1992)			
X	BY	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P			
Vr_	<u> </u>	7(6):334-339 (1994)			
		Potgens et al., "Measurement of tissue factor messenger RNA levels in human			
3	BZ	endothelial cells by a quantitative RT-PCR assay," Thrombosis and Hemostasis 71:208-			
<u>v</u>	<u> </u>	213 (1994)			
	CA	Sandberg-Nordqvist et al., "Characterization of Insulin-Like Growth Factor 1 in Human			
8	_ UA	Primary Brain Tumors," Cancer Research 53:2475-2478 (1993)			
	СВ	Sato et al., "Correlation of Neovascularization and vascular endothelial growth factor in			
0	0.5	human renal cell carcinoma," <u>Gan Ko Kagaku Ryoho</u> 24:389-394 (1997)			
8	cc	Schlessinger et al., "Regulation of growth factor activation by proteoglycans: What is the			
COX		role of the low affinity receptors?" Cell 83:357-360 (1995)			
(A)	CD	Shiang et al., "Mutations in the Transmembrane Domain of FGFR3 Cuause the Most			
0'	لـــــــــا	Common Genetic Form of Dwarfism, Achondroplasia," Cell 78:335-342 (1994)			
0	CE	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type			
44		tyrosine kinase gene (fit) closely realted to the fms family," Oncogene 5:519-524 (1990)			
(A)	CF	Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate			
	igwdot	hypoxia-initiated angiogenesis," Nature 359:843-845 (1992)			
Ø	CG	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian			
	I	Cancer," <u>Science</u> 244:707-712 (1989)			
(D)	СН	Tavormina et al., "Thanatophoric dysplasia (types I and II) caused by distinct mutations in			
	 _	fibroblast growth factor receptor 3," Nature Genetics 9:321-328 (1995)			
(D)	CI	Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain			
	لـــــا	Metastases," <u>AMPIS</u> 100:713-719 (1992)			

EXAMINER:	h	n	DATE CONSIDERED:
EXAMINER: In citation if not in	nitial if reference is consider on conformance and not c	dered, whether or not citation onsidered. Include a copy of	n is in conformance with MPEP 609; Draw line through of this form with next communication to applicant.

FORM PTO-1449	ATTY. DOCKET NO. 238/046	SERIAL NO. 09/186,475
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT PE	APPLICANT: Annie Fong et al.	
(Use several sheets if necessart) O MAY 0 3 1999	FILING DATE: November 4, 1998	GROUP: 1614
3		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
(P)	Cl	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)		
(P)	СК	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," J. Biol. Chem. 265:19461-19466 (1990)		
(M)	CL	Webster et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia," <u>EMBO J.</u> 15:520-527 (1996)		
D	СМ	Weidner et al., "Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma," New England J. Medicine 324:1-7 (1991)		
8	CN	Xu et al., "Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma," <u>Hum. Pathol</u> . 28:206-213 (1997)		
Ø	со	Zhang et al., "Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice," <u>J. Clin. Invest.</u> 94:1320-1327 (1994)		

	<u> </u>	
EXAMINER:		DATE CONSIDERED: / /
Y	<u> </u>	SAITE CONSIDERED.
/	$1 \sim 1 \sim 1$	1012110 1

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.